Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Neuropharmacology. 2015 Feb 3;93:15–27. doi: 10.1016/j.neuropharm.2015.01.017

Figure 1.

Figure 1

A, Experimental paradigm of chemical administration in a rat model of DFP-induced status epilepticus. For the pre-treatment experiment, rats were injected with 1 dose of the EP2 antagonist TG6-10-1 (5 mg/kg, ip) or vehicle one hour prior to DFP. For post-treatment following DFP, rats were injected with multiple doses (red = 2 doses and blue = 6 doses) of TG6-10-1 or vehicle beginning 80-150 minutes from the onset of SE. B, plasma concentration of untreated rats that received TG6-10-1 (n = 3 rats) ip (10 mg/kg) or po (20 mg/kg). The plasma levels of TG6-10-1 decreased over time. However, the brain to plasma ratio (C) increased in rats administered TG6-10-1 orally.